

University of Texas MD Anderson Cancer Center

Intermediate Level

.15 ASHA CEUs

Hands On the MANTLE Trial Results: What Does This Mean for My Dysphagia Practice?

Available until 12/31/2025

Level: Intermediate

Course Structure:

This course is an asynchronous course, available on-demand. Participants will have the opportunity to complete course requirements via a recorded webinar.

Course Description:

This course intends to bridge the recently published results of the MANTLE trial to dysphagia practice. In this course, participants will gain interdisciplinary perspectives on radiation fibrosis and manual therapy as it relates to cervical fibrosis and late radiation associated dysphagia. The course will emphasize practical ways to consider integrating manual therapy into dysphagia care models. Insights about radiation fibrosis will be considered from rehabilitation and radiation oncology perspective. Presenters will share algorithms for screening, clinical measurement, and integration of fibrosis mitigation strategies for late-RAD.

Course Objectives:

Participants will be able to:

- 1. Describe radiation fibrosis syndrome in the neck and pharynx as it relates to late radiation-associated dysphagia and cervical posture.
- 2. Describe results of MANTLE trial examining manual therapy in patients with late radiationassociated dysphagia.
- 3. Describe practical ways the speech pathologist can integrate manual therapy into dysphagia care.

Agenda:

- 0-5 Introduction
- 5-17 RFS of the neck and swallow (Stubblefeld)
- 17-32 Hands on the MANTLE trial results (McMillan)
- 32-47 Fitting manual therapy into my dysphagia care (Porsche)

- 47-59 It wasn't me! Radiation fibrosis a radiation oncologist's perspective (Fuller)
- 59-90 Moderated Panel All Faculty (Hutcheson)

No partial credit will be given for this course.

Completion Requirements:

In order to receive ASHA CEUs, you must complete the following—

- 1. Watch the webinar in full, which will be monitored through the website.
- 2. Complete a post-course evaluation and survey within 48 hours of watching the webinar in full.
- 3. The post-course assessment will include a multiple-choice test, which must be completed with 100% accuracy. The learner will have unlimited attempts.

Link to Post-Course Evaluation

Policies: Please see home page

How to access the live event:

- 1. Log into your account
- 2. Click on the "View Content" tab, where you will see the course title.
- 3. Click "Launch Zoom Webinar" at the bottom of the course.
- 4. Enter requested information and click "**Register**" using the same email address used to register for the activity (this can be done ahead of time and added to your calendar)
- 5. The day of the event, click "Join Meeting"

Note: If participating from a mobile device, you must download the Zoom mobile app to view this live event.

Bios/Disclosures:

Dr. Kate Hutcheson, Ph.D.

Dr. Kate Hutcheson is a tenured Professor and Deputy Director of Clinical Research in the Department of Head and Neck Surgery with dual appointment in the Division of Radiation Oncology at the University of Texas MD Anderson Cancer Center. She serves as Section Chief and Research Director for the Section of Speech Pathology and Audiology. Dr. Hutcheson is a certified speech-language pathologist practicing in oncology for 20 years, a Board Certified Specialist in Swallowing and Swallowing Disorders (BCS-S), and holds a Doctorate Degree in Epidemiology. She leads an internationally recognized, extramurally funded clinical research program. She has authored over 175 journal articles with funding support from the National Institutes of Health, Patient Centered Outcomes Research Institute, the MD Anderson Institutional Research Grant Award program, and the

CPRIT UT Health Innovation Training Program. She is an Associated Editor for the Head and Neck and Dysphagia journals. She is a passionate clinician and educator who lectures nationally and internationally on radiation associated dysphagia and head and neck cancer rehabilitation.

Disclosures:

Dr. Hutcheson receives research funding from the National Institutes of Health/National Cancer Institute (R01CA271223, R01CA273984), Patient Centered Outcomes Research Institute (PCORI 1609-36195), the MD Anderson Institutional Research Grant Program, and Atos Medical. Unrestricted Educational Grant outside this Program from Atos Medical. Developer and PI of the DIGEST method. Dr. Hutcheson receives no royalties or personal fees related to this DIGEST content.

Dr. Michael Stubblefield, MD

Dr. Stubblefeld is the former Chief of Cancer Rehabilitation at Memorial Sloan-Kettering Cancer Center. He now serves as Medical Director of Cancer Rehabilitation at Kessler Institute for Rehabilitation, and National Medical Director for Select Medical's ReVital Cancer Rehabilitation Program. He is a Clinical Professor in the Department of Physical Medicine and Rehabilitation at the Rutgers New Jersey Medical School. He is board certified in Physical Medicine and Rehabilitation (PM&R), Internal Medicine, and Electrodiagnostic Medicine. His primary clinical expertise is in the identification, evaluation, and rehabilitation of neuromuscular, musculoskeletal, pain, and functional disorders resulting from cancer and its treatment, particularly those caused by radiation and neurotoxic chemotherapy. Dr. Stubblefield is an accomplished researcher who has published extensively, not only in the rehabilitation literature, but in oncology, pain management, palliative care, neurophysiology, and other journals. He has authored numerous review articles and book chapters in the field of cancer rehabilitation and is the editor of Cancer Rehabilitation: Principles and Practice, the only comprehensive textbook in this emerging field now in its second edition. Dr. Stubblefield is a fierce advocate for the development of cancer rehabilitation and survivorship programs and champions their role in restoring function and quality of life to cancer patients.

Disclosures:

Dr. Stubblefield is employed by Kessler Institute for Rehabilitation and receives a salary. He also receives financial support (honoraria) from Tactile Medical on their Advisory Board and as a lecturer. He has no relevant non-financial relationships to disclose.

Holly McMillan, MCD, SLP

Ms. McMillan is a Senior Clinical Research Speech-Language Pathologist and Co-Director of Trismus Clinic at the University of Texas MD Anderson Cancer Center. She is also a doctoral student at the University of Texas School of Public Health, a licensed massage therapist, and certified lymphedema therapist with expertise in oncology and head and neck cancer rehabilitation. Ms. McMillan serves as lead clinician on and active NIH funded clinical trial examining manual therapy for late effect

dysphagia and is a collaborator on several NIH funded clinical trials in head and neck cancer survivorship.

Disclosures:

Ms. McMillan is employed by MD Anderson Cancer Center and receives a salary. She has no relevant non-financial relationships to disclose.

Christine Porsche, MS, SLP

Ms. Porsche a Senior Speech Pathologist, Clinical Coordinator, and Certified Lymphedema Therapist at MD Anderson Cancer Center. She is a collaborator on NIH-funded clinical research protocols and has been an invited speaker at several regional and national conferences.

Disclosures:

Ms. Porsche is employed by MD Anderson Cancer Center and receives a salary. She has no relevant non-financial relationships to disclose.

Dr. C. David Fuller, MD, Ph.D.

Dr. Fuller is a Professor and Physician within the Division of Radiation Oncology at the University of Texas MD Anderson Cancer Center in Houston, TX.

Disclosures:

Dr. Fuller is employed by MD Anderson Cancer Center and receives a salary. He has no relevant non-financial relationships to disclose.

Sarah Sheridan, MS, SLP

Ms. Sheridan is a Speech-Language Pathologist at the Kessler Institute for Rehabilitation in West Orange, NJ.

Disclosures:

Ms. Sheridan is employed by Kessler Institute for Rehabilitation and receives a salary. She has no relevant non-financial relationships to disclose.